1. Opening Remarks
Trioday, a product of Cipla Ltd., falls under the category of fixed-dose combination (FDC) antiretrovirals. It is prescribed for individuals infected with HIV. The convenience of a single-tablet, once-daily regimen has made it a valuable tool in modern HIV care, merging three separate drugs into one oral dose.
The arrival of FDCs like Trioday has reshaped HIV treatment by promoting better adherence, decreasing the number of pills patients must handle, and ultimately leading to improved health outcomes. This piece offers a full-spectrum review of Trioday, touching on its formulation, pharmacological action, clinical indications, adverse reactions, safety measures, and approval status.
2. Ingredient Breakdown
2.1 Active Components and Their Potencies
Three antiretroviral substances from two distinct classes make up Trioday :
Drug Name Quantity per Tablet Class
Efavirenz 600 mg Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Lamivudine 300 mg Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Tenofovir Disoproxil Fumarate 300 mg Nucleoside Reverse Transcriptase Inhibitor (NRTI)
2.2 Physical Description and Packaging
Trioday is manufactured as a film-coated tablet intended to be swallowed. The Philippine Food and Drug Administration (FDA) verification portal states that the product is enclosed in a white opaque HDPE bottle fitted with a white opaque screw cap (not child-resistant). Each bottle contains 30 tablets , sufficient for a 30-day course.
2.3 Manufacturer and Supply Chain
The manufacturing site for Trioday is Cipla Limited's Goa (Unit VII) facility in India . Cipla enjoys a global reputation for producing cost-effective HIV medications, particularly for low- and middle-income nations. Distribution channels differ by geography; for example, Phil Pharmawealth, Inc. serves as the importer and distributor in the Philippines .
3. Understanding the Mechanism of Action
Trioday's therapeutic efficacy is rooted in the distinct yet complementary actions of its three components, each of which disrupts a specific phase of the HIV replication process.
3.1 Efavirenz's Role (NNRTI)
Efavirenz operates by directly attaching to the reverse transcriptase enzyme and disabling it. Unlike NRTIs, it does not require intracellular conversion to an active form. Instead, it fits into a hydrophobic pocket near the enzyme's active site. This binding causes a conformational shift that prevents the enzyme from transcribing viral RNA into DNA, effectively stopping viral replication at an early stage.
3.2 Lamivudine's Function (NRTI)
Lamivudine is structurally similar to the natural nucleoside deoxycytidine. It competes for incorporation into the elongating viral DNA chain. Once inserted, it terminates further chain elongation because it lacks a 3'-hydroxyl group — a necessary component for adding more nucleotides. This premature termination results in a non-functional viral genome.
3.3 Tenofovir Disoproxil Fumarate's Contribution (NRTI)
Tenofovir acts as an analog of adenosine monophosphate. After entering cells, it undergoes conversion to its active metabolite, tenofovir diphosphate. This active form then competes with the natural substrate deoxyadenosine triphosphate. When tenofovir is incorporated into the viral DNA chain, it again halts further extension, leaving the viral genetic material incomplete.
The combination of three drugs from two classes produces a synergistic antiviral effect. By targeting HIV through multiple mechanisms, Trioday delivers robust viral suppression while minimizing the emergence of drug-resistant strains — a key consideration in lifelong HIV therapy .
4. Authorized Indications
Trioday is approved for the management of Human Immunodeficiency Virus-1 (HIV-1) infection in adult patients . It is designed to be used as a component of a broader HIV treatment strategy.
A crucial point to reiterate is that Trioday does not eradicate HIV or cure AIDS. It functions as a long-term suppressive therapy that keeps viral replication in check, enabling the immune system to repair and function more effectively. By controlling viral activity, Trioday contributes to:
A reduced likelihood of opportunistic diseases
Enhanced immune competence (increased CD4 counts)
Fewer HIV-associated complications
Prolonged survival and better quality of life
5. Efficacy and Advantages in Clinical Practice
5.1 Achieving Viral Suppression
Clinical evidence consistently demonstrates that fixed-dose combinations containing efavirenz, lamivudine, and tenofovir are highly capable of achieving and sustaining undetectable viral loads. With disciplined daily use, the vast majority of patients reach HIV RNA levels below 50 copies/mL.
5.2 Immune System Recovery
By suppressing viral replication, Trioday allows the immune system to regenerate. Patients typically experience meaningful elevations in CD4 cell counts, which are essential for defending against infections. This immune reconstitution lowers susceptibility to AIDS-defining conditions and enhances overall health.
5.3 Simplifying Treatment Adherence
The convenience of a once-daily single tablet cannot be overstated compared to older multi-pill regimens. Simplification reduces the daily burden on patients, making consistent adherence more achievable. The manufacturer advises taking the tablet on an empty stomach, preferably at bedtime, to improve absorption and reduce the intensity of side effects .
6. Side Effect Profile
6.1 Frequently Encountered Adverse Effects
Most side effects associated with Trioday are transient and typically resolve within the initial weeks of therapy. Commonly reported adverse reactions include :
Neurological and psychiatric symptoms:
Lightheadedness
Insomnia
Inability to focus
Vivid or unusual dreams
Cephalalgia (headache)
Depressed mood
Nervousness
Gastrointestinal disturbances:
Queasiness
Emesis
Loose stools
Cramping or pain in the abdomen
Miscellaneous:
Cutaneous rash
Lassitude and lack of energy
Pyrexia (fever)
Cough
Arthralgia and myalgia (joint and muscle discomfort)
6.2 Serious Adverse Events
Although infrequent, certain serious side effects demand urgent medical evaluation :
Metabolic and hepatic concerns:
Lactic acidosis (accumulation of lactic acid in the bloodstream)
Hepatic steatosis (fatty liver)
Hepatitis and liver failure
Hypertriglyceridemia and hypercholesterolemia
Renal and skeletal issues:
Nephropathy (blood in urine, elevated serum creatinine)
Fanconi syndrome (proximal renal tubular dysfunction)
Osteomalacia (bone softening)
Diminished bone mineral density
Dermatological reactions:
Severe rash including Stevens-Johnson syndrome (rare but life-threatening)
Erythema multiforme
Other serious events:
Pancreatitis
Immune reconstitution inflammatory syndrome (IRIS)
Patients who develop abdominal pain, anorexia, dark urine, icterus (yellowing of skin or eyes), or dyspnea (difficulty breathing) should seek immediate medical care .
7. Contraindications and Precautionary Measures
7.1 Absolute Contraindications
Trioday is contraindicated in the following circumstances :
Documented hypersensitivity to any constituent of the formulation
Advanced liver disease or hepatic decompensation
Concomitant use with specific medications (detailed in drug interactions)
7.2 Use in Specific Populations
Pregnancy and Lactation:
Trioday has teratogenic potential, so women must avoid becoming pregnant during treatment and for 12 weeks after discontinuation. Effective barrier contraception (e.g., condoms) along with another contraceptive method is recommended for women of childbearing potential. A pregnancy test may be required prior to initiation . Breastfeeding is discouraged for HIV-positive women because the virus can be transmitted to the infant via breast milk .
Renal Insufficiency:
Tenofovir is primarily eliminated through renal excretion. Patients with pre-existing kidney disease or risk factors for nephrotoxicity require regular monitoring of renal parameters. Dosage adjustments may be necessary .
Hepatic Impairment:
Individuals with a history of liver disease, including chronic hepatitis B or C co-infection, need close monitoring because antiretroviral therapy can exacerbate underlying hepatic conditions.
Geriatric Use:
Clinical data regarding Trioday use in patients aged 65 years and older are limited.
7.3 Important Safety Warnings
Lactic Acidosis: This uncommon but critical condition presents with tachypnea (rapid breathing), somnolence, nausea, and abdominal pain. It requires emergency intervention.
Bone Health: Tenofovir has been associated with reduced bone mineral density. Patients should engage in regular weight-bearing exercise and consider calcium and vitamin D supplementation as advised by their physician .
Immune Reconstitution Syndrome: As the immune system rebounds, inflammatory responses to residual opportunistic infections may occur. Prompt diagnosis and treatment are necessary.
Drug-Drug Interactions: Trioday has a high potential for interactions, particularly with medications metabolized via the CYP450 enzyme system. Patients must disclose all concurrent drugs, including over-the-counter products and herbal supplements like St. John's Wort, which can significantly diminish Trioday's efficacy .
8. Clinically Relevant Drug Interactions
Trioday carries a substantial risk of drug interactions because efavirenz induces or inhibits various liver enzymes, particularly CYP3A4 and CYP2B6. Notable interactions include :
Interacting Category Specific Agents Potential Consequence
Antihistamines Astemizole, Terfenadine Risk of serious cardiac arrhythmias
Cardiovascular drugs Bepridil, certain beta-blockers Altered cardiac conduction
Prokinetic agents Cisapride Cardiotoxicity
Ergot alkaloids Ergotamine, Dihydroergotamine Ergot toxicity
Benzodiazepines Midazolam, Triazolam Prolonged sedation, respiratory depression
Antipsychotics Pimozide Cardiac arrhythmias
Antidepressants Certain tricyclics (imipramine, amitriptyline) Altered plasma levels
Direct-acting antivirals (HCV) Elbasvir/Grazoprevir Reduced HCV treatment efficacy
Herbal remedies St. John's Wort Reduced Trioday efficacy
Anticonvulsants Carbamazepine, Phenytoin, Phenobarbital Altered levels of both agents
Antifungals Ketoconazole, Itraconazole Reduced antifungal efficacy
Antibiotics Clarithromycin, Rifampin, Rifabutin Multiple complex interactions
Alcohol consumption should be avoided during Trioday therapy, as it can exacerbate side effects and increase the risk of hepatotoxicity .
9. Dosing Instructions
9.1 Recommended Adult Dosage
The standard adult dose is one tablet taken once daily. The tablet should be swallowed whole without crushing, chewing, or breaking. Administration should occur on an empty stomach, ideally at bedtime, to enhance tolerability of central check here nervous system side effects .
9.2 Management of Missed Doses
If a dose is omitted, it should be taken as soon as the patient remembers unless the next scheduled dose is imminent. Doubling the dose to compensate for a missed one is not advised .
9.3 Overdose Protocol
In the event of suspected overdose, immediate medical attention is required. Patients should retain the medication container to provide accurate information about what was ingested .
10. Regulatory Status and International Availability
10.1 Approved Markets
Trioday has secured regulatory approval in numerous countries. As documented by the Philippine FDA, Trioday holds registration number DR-XY47585, with an issuance date of December 7, 2021, and validity extending until December 7, 2024 .
10.2 Expanding Access Globally
Cipla has been a trailblazer in making antiretroviral therapy accessible in resource-constrained settings. The affordability of Trioday has significantly bolstered global HIV/AIDS control initiatives, particularly in Africa and Southeast Asia.
In 2015, Trioday was introduced in Uganda as a once-daily regimen aimed at enhancing adherence and retention in HIV care. The launch was presided over by Uganda's then-Prime Minister, Dr. Ruhakana Rugunda, who emphasized the importance of local manufacturing capabilities in tackling the HIV epidemic .
11. Pricing Information
The cost of Trioday varies by country and distribution channel. In the Indian market, prices range from approximately ₹2,365 to ₹3,455 per bottle of 30 tablets . This variation stems from differences in supply chains, taxation, and vendor pricing.
Several generic equivalents and substitute brands are available in different regions, such as:
Avonza (Mylan Pharmaceuticals)
Telura (Mylan Pharmaceuticals)
Vonaday (Emcure Pharmaceuticals)
Dinmek (MSD Pharmaceuticals)
12. Guidance for Patients
Healthcare professionals should educate patients on the following points:
Consistency is key: Skipping doses increases the risk of treatment failure and drug resistance. Take the medication at the same hour each day .
No cure: Trioday does not eliminate HIV, and patients remain capable of transmitting the virus. Safer sex practices are essential.
Early side effects are common: Initial effects like dizziness, unusual dreams, and nausea typically subside within 2–4 weeks. Bedtime dosing helps mitigate these .
Do not stop abruptly: Discontinuing therapy without medical supervision can lead to viral rebound and resistance.
Regular monitoring is mandatory: Frequent follow-ups and laboratory tests (liver function, kidney function, viral load, CD4 count) are necessary .
Avoid pregnancy: Women of childbearing potential must use effective contraception during treatment and for 12 weeks after stopping .
Full disclosure of medications: Always inform healthcare providers about all drugs, including OTC products and herbal supplements.
13. Concluding Remarks
Trioday (Cipla) stands as a meaningful advancement in HIV pharmacotherapy, offering a potent, user-friendly, and cost-effective fixed-dose combination. By consolidating efavirenz, lamivudine, and tenofovir into a single daily tablet, it addresses a major barrier in chronic HIV management: consistent medication adherence.
Although Trioday carries risks of adverse effects and requires diligent monitoring, its proven benefits in viral suppression and immune restoration are undeniable. Fixed-dose combinations of this nature have been instrumental in transforming HIV from a fatal disease into a manageable chronic condition, particularly in resource-limited settings where Cipla's affordability mission has had profound impact.
As with any antiretroviral agent, Trioday should be prescribed and overseen by qualified healthcare providers as part of an integrated HIV care plan. Ongoing research continues to refine treatment paradigms, but fixed-dose combinations like Trioday remain foundational to global HIV control strategies.
References (Authentic & Unchanged)
Philippine Food and Drug Administration. (2024). *FDA Verification Portal - Product Information DR-XY47585*. Retrieved from https://verification.fda.gov.ph/
Farmako. (n.d.). Trioday Tablet - Uses, Side Effects, and Composition. Retrieved from https://farmako.in/
Oddway International. (2024). Trioday Tablets - Product Information. Retrieved from https://www.oddwayinternational.com/
Philippine Food and Drug Administration. (2021). *Human Drugs View - DR-XY47585*. Retrieved from https://verification.fda.gov.ph/
IndiaMART. (n.d.). *Trioday 30 Tablets - Product Details*. Retrieved from https://www.indiamart.com/
Oddway International. (2025). Efavirenz Lamivudine Tenofovir Tablets. Retrieved from https://www.oddwayinternational.com/
PharmEasy. (2025). *Trioday Bottle of 30 Tablets - Product Information*. Retrieved from https://pharmeasy.in/
1mg. (n.d.). Trioday - Uses, Side Effects, Composition, and Expert Advice. Retrieved from https://www.1mg.com/
Antiaids.org. (2015). Uganda makes new AIDS drug. Retrieved from http://old.antiaids.org/